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From the Editor’s Desk
Dear Readers
The past surreal year of 2020 occupies a different
significance in the history of the world. So far, we
all have responded positively. The technology has
bridged the gap between individuals even as social
distancing was practiced. During this time our
LABRAD was digitalized and is now also available
on AKU website: https://www.aku.edu/mcpk/
pathology/labrad/Pages/from-the-editors-desk.aspx
The current issue is thematic on ‘Paediatric
Diagnostics’. A compilation of articles covering the
various aspects of paediatric disorders with relevant
investigations are being presented here. We have some
interesting discussions like diagnostic tools for HIV
in infants, fecal calprotectin in inflammatory bowel
disease, pleuropulmonary blastoma a rare tumor of
infancy, biotinidase deficiency, utility of chromosomal
microarray, hemoglobin variants analysis and
intussusception in paediatric patients.

Pakistan suffers from a high burden of rare diseases
due to the prevalent practice of consanguineous
marriages, lack of awareness, and non-availability
of clinical metabolic services. Early this year,
Department of Pathology and Laboratory Medicine,
in collaboration with Pak-IMD-Net and Pakistan
Society of Chemical Pathologists launched an e-portal
‘Ek Sath’ to support children/patients with inherited
metabolic disorders and their families. To visit Ek
Sath’s website click the link: https://fal.cn/EkSath
We value your opinion and feedback regarding topic
selections, educational and resource materials we can
provide and ideas on how we can better network and
communicate using LABRAD.
Dr Lena Jafri,
Editor LABRAD

Laboratory Diagnostic Tools for HIV in
Neonates and Infants
Dr Safia Moin and Dr Mohammad Zeeshan
Microbiology

Early and optimal laboratory diagnosis has an
important role in the mortality and morbidity of HIV
infected children as early antiretroviral therapeutic
(ARTs) interventions in less than five years of age
have shown better life long outcomes. One third
population in this age bracket lost their battle of
lives in infancy if do not get ARTs and proper care
on time. However, the limitations and challenges in
laboratory diagnosis and confirmation specifically in
this age group must be kept under consideration while
confirming the clinical suspicion.
Proper utility of the following diagnostic tools in
the first few months of life can be helpful for child’s
health:

1. Nucleic acid amplification test (NATs):
l
It is the recommended diagnostic platform in
		 infants and children up till 18 months of age
		 and must be done at 4–6 weeks of age or at
		 the earliest opportunity thereafter for all HIV
		expose infants
l
HIV DNA performed on whole blood
		 specimen or Dried Blood Sample (DBS); HIV
		 RNA on plasma or DBS;
l
Before starting ARTs, a second specimen
		 should be collected to confirm the initial
		 positive virological test result
2. HIV antibody detection:
l
Due to transplacental transfer from HIV
3
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confirmed mother, presence of antibodies in
new born serum does not confirm the
diagnosis and therefore are not recommended
up till 18th months of child’s life.
l
Antibody-negative results may suggest that
		 infants are unexposed and or uninfected,
		 however if the infant is on breastfeeding
		 the risk of acquisition from HIV confirm
		 mother continues throughout the entire
		breastfeeding period.
l
HIV-exposed infants who are well, undergo
		 HIV serological testing at around nine months
		 of age (or at the time of the last immunization
		 visit). Those who have reactive serological
		 assays at nine months should have a 		
		 virological test to identify HIV infection and
		 the need for ART.

l

		
		

Infants with signs or symptoms suggestive of
HIV infection undergo HIV serological testing
and, if positive (reactive), virological testing.

3. Ultrasensitive p24 (Up24) antigen:
l
It is detected through ELISA-based
		 technology and was being considered as
		 reliable tool, however, after the availability of
		 easy and economical NATs and difficulty in
		 procurement of p24 commercially available
		 kit has made this test almost redundant.
4. Rapid diagnostic test:
l
Antigen/antibody combination immunoassays
		 that detect HIV-1/2 antibodies as well as HIV		 1 p24 antigen are not recommended for 		
		 1diagnosis of HIV infection in infants.

Table 1: Summary of recommended testing approaches and required actions
Category

Test required

Well, HIV-exposed infant

Purpose

Virological testing at 4–6 weeks To diagnose
of age

Infant – unknown HIV exposure Maternal HIV serological test or To identify or confirm HIV
infant HIV serological test
exposure

Action
Start ART if HIV-infected
Need virological test if HIVexposed

Well, HIV-exposed infant at 9
months

HIV serological test (at last
immunization, usually 9
months)

To identify infants who have
1. HIV seropositive need
persisting HIV antibody or have
virological test and continued
seroreverted
follow up
2. HIV negative, assume
uninfected, repeat testing 		
required if still breastfeeding

Infant or child with signs and
symptoms suggestive of HIV

HIV serological test

To confirm exposure

Perform virological test if
<18months of age

Well or sick child seropositive
>9 months and < 18 months

Virological testing

To diagnose HIV

Reactive– start HIV care and
ART if under 24 months, or
based on national start criteria if
24 months or more

Infant or child who has
completely discontinued
breastfeeding

Repeat testing six weeks or more To exclude HIV infection after
after breastfeeding cessation–
exposure ceases
usually initial HIV serological
testing followed by virological
testing for HIV-positive child
and < 18 months of age

Infected infants and children <
24 months of age, need to start
HIV care, including ART

Higher Risk: Infants born to mothers with HIV who did not receive prenatal care, did not receive antepartum or
intrapartum ARV drugs, received intrapartum ARV drugs only, who initiated ART late in pregnancy (during the late
second or third trimester), received a diagnosis of acute HIV infection during pregnancy, or had detectable HIV viral
loads close to the time of delivery, including those who received combination ARV drugs and did not have sustained viral
suppression.
Age at NAT testing

Birth

14-21 days

1-2 months

2-3 monthsa

4-6 months

For higher risk infants additional virologic diagnostic testing is recommended at birth and 2 to 6 weeks after cessation of
ARV prophylaxis (i.e., at 8-12 weeks of life).
a

Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test
Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV and Who Are at Higher Risk of Perinatal HIV Transmission
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Low Risk: Infants born to mothers with HIV who received standard ART during pregnancy and who had
sustained viral suppression (usually defined as confirmed HIV RNA level below the lower limits of detection of
an ultrasensitive assay) with no concerns related to maternal adherence.
Age at NAT testing

14-21 days

1-2 monthsa

4-6 months

Test may be timed to occur at least 2 weeks after cessation of ARV prophylaxis

a

Key: ART = antiretroviral therapy; ARV = antiretroviral; NAT = nucleic acid test
Recommended Virologic Testing Schedules for Infants Who Were Exposed to HIV and Who Are at Low Risk of Perinatal HIV Transmission

Intussusception in Paediatric Patients: Role of
Radiology in Diagnosis and Management
Dr Shaista Afzal and Dr Amna A. Saeed
Radiology and BBS Department

Introduction
Intussusception is one of the most common causes
of acute bowel obstruction in paediatric patients.
It typically occurs between three to 24 months of
age, with a male: female ration of 2:1. It is due to
invagination of intussusceptum (proximal bowel
segment) into intussuscepiens (more distal bowel
segment). Hypertrophy of lymphoid tissue in the
wall of the small bowel plays an important role in the
development of intussusception. In five to ten percent
of cases, pathological lead points are identified and
include polyps, Meckel’s diverticulum, duplication
cyst etc. The classical symptoms of intussusception
include abdominal pain, vomiting, and bloody (red
currant jelly) stools. However, this triad of symptoms
is seen in less than 25 percent of cases, and other
clinical features include a palpable abdominal lump in
the right upper quadrant associated with emptiness of
the right iliac fossa.

imaging approach includes x ray abdomen and
ultrasound for exclusion of other causes of obstruction
and for confirmation of intussusception. Although
x ray abdomen has low sensitivity for detection of
intussusception, i.e., around 45 percent, it helps excludes
the presence of perforation and pneumoperitoneum. The
imaging features seen on an abdominal radiograph are
an elongated soft tissue density mostly in the right side
of abdomen, with signs of bowel obstruction proximally,
and paucity of gas distally (Figure 1).

Diagnosis
Intussusception, if not diagnosed early, may lead to
compromised blood supply to the bowel, which can
result in bowel infarction, perforation, peritonitis and
even death. Hence, prompt diagnosis is warranted
to avoid these grave consequences. The diagnostic

Figure 1: Soft tissue mass in lower abdomen suggesting colocolic
intussusception
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The reported accuracy of ultrasound in diagnosis of
intussusception approaches 100 percent. The classical
ultrasound features of intussusception include
target/crescent in donut appearance in transverse
section, and pseudo kidney/ sandwich appearance
in longitudinal section (Figure 2). Ultrasound also
helps in evaluation of its reducibility (Figure 3). The
features associated with reduced success rates of
air enema includes small bowel obstruction, more
distil location, trapped inter bowel loops fluid and
lack of Doppler flow in the bowel wall. However, the
presence of lymph nodes within the intussusception or
ascites has not been reported to affect the outcome of
this procedure.

VOL 46, ISSUE 3
The success rates of air enema reduction and
hydrostatic reduction under ultrasound guidance
are almost similar however, the advantage under
ultrasound guidance is avoidance of ionizing
radiations. These two techniques are associated
with low incidence of perforation. Barium enema
reduction of intussusception may result in peritoneal
spillage and chemical peritonitis in case of
perforation and has thus become less popular. Prior
to image guided reduction, surgical consultation is
essential to exclude the presence of complications
including peritonitis, shock, and pneumoperitoneum,
as the procedure is contraindicated in such
conditions.

Figure 2: Ultrasound right upper abdomen shows target/ crescent in donut appearance
in transverse section and pseudo kidney/ sandwich appearance in longitudinal section,
consistent with intussusception

During the procedure of hydrostatic enema,
saline solution is slowly introduced by gravity
into the rectum through a rectal tube that is
firmly taped in place. The fluid column is
maintained at a height of three feet above the
patient. It is recommended to sustain pressure
for not more than three minutes in case of
a non-moving intussusception, and attempt
the process not more than three times. The
pressure thus achieved forces retrograde
movement of bowel through the ileocecal
valve.

The method of air reduction involves
introduction of air
through a rectal
catheter (Figure 4).
The pressure within
the colon should not
exceed 120 mm Hg.
With the reduction
of intussusception
(Figure 5), the
intracolic pressure
Figure 3: The ultrasound features seen with successful reduction of intussusception i.e., falls, and hence, the
no trapped inter bowel loops fluid and normal Doppler flow in bowel wall.
presence of pressure
gauge and pop off
Management
mechanism is very helpful.
The reported success rate
Once diagnosed on imaging, the next step towards
of air enema reduction of
patient’s management is the use of enema as the first
intussusception varies from
line treatment. The technique is to instill air, saline or
51 percent to 95 percent.
contrast through rectum into the colon under real time
imaging. The pressure builds up as a result thus helps
In those patients with
to reduce the intussusception.

Figure 4: Instrument for Pneumatic reduction of intussusception
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60 minutes.
Recurrent intussusception
after image guided reduction
ranges from five percent to
20 percent and half of these
occur within 48 hours. These
show a higher incidence of
pathological lead points.
Recurrent intussusception
can be managed nonoperatively and does not
necessarily warrant surgery,
even if it occurs a number of
times.
Conclusion

Figure 5: Soft tissue due to intussusception in the region of cecum (a), which started reducing with pneumatic
reduction. Complete reduction of intussusception was achieved and free reflux of air is seen into the small
bowel loops (b).

partial reduction of intussusception at first attempt,
a repeat enema has been reported to be successful
in around 50 percent of cases. The suggested time
interval between these repeated enemas is from 30 to

It is important to recognize
the imaging features of
intussusception for early diagnosis and to be aware
of its possible radiological management options for
prompt treatment and hence to reduce morbidity and
mortality.

Fecal Calprotectin as an Inflammatory Marker
in Inflammatory Bowel Disease
Ms Iffat Arman
Clinical Chemistry

Calprotectin (CP) is a zinc- and calcium-binding
protein of the S100 family expressed mainly by the
cytoplasm of neutrophils. It participates in leukocyte
interactions with the endothelium, cellular adhesions
leading to the recruitment of leukocytes to inflamed
intestinal tissue, and with the inflammatory and
thrombogenic response of endothelial cells.
Calprotectin is recommended for the diagnosis,
assessment of relapses, follow up and response
to treatment in inflammatory conditions, such as
inflammatory bowel disease (IBD), celiac disease,
necrotizing enterocolitis, acute appendicitis, intestinal
cystic fibrosis etc. the fecal CP remains stable for up
to one week when stored at room temperature, thus it
can be used as an accurate marker for inflammatory

disorders of gut, especially IBD and it is now a
recommended biomarker for optimizing management
of IBD patients. Its concentration is elevated in both
Crohn’s disease and ulcerative colitis, while treatment
leads to a decrease in CP concentrations parallel to
clinical improvement, reflecting mucosal healing.
In Aga Khan Hospital fecal CP test is performed and
is intended for use in the quantitative determination
of human CP levels in stool samples with reference
range of <43.2ug/G. It is a good potential marker for
diagnosis and prognosis of IBD patients. However,
caution should be practiced while interpreting its
results, as its levels can also be elevated in other
inflammatory diseases, infectious diseases of gut and
even in some neoplastic paediatric tumors.
7
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Spectrum of Tools for the Detection of Enteric
Pathogens in A Clinical Laboratory
Dr Salima Rattani and Dr Mohammad Zeeshan
Microbiology

Diarrheal diseases in children, acute or chronic,
can have serious long term implications and health
sequels. It contributes considerably in disease
burden of low and middle income countries. The
spectrum of causative agents is extensive depending
upon nutritional status, socioeconomic condition,
underlying comorbidities and the geographic domain.
The paradigm shift in laboratory diagnostic methods
has proven the improved disease outcome. However,
conventional methods are still being used as front line
modalities in resource limited health care settings.
1. Stool Microscopy
a. Direct and concentration methods:
Direct microscopy is one of the oldest
laboratory diagnostic procedure but still
equally useful and cost effective for
identification of enteric ova and parasites. It
depends upon the microscopist skills; further,
the conventional concentration methods are
laborious and messy. Therefore, for improving
the yield and reducing the cumbersome
process, the utility of concentration tube with
build-in Millipore filter has been introduced
(Figure 1).

Figure 1: Fecal concentration tube and processing

8

		 (a) Unassembled flat-bottomed 			
			 mixing chamber and filter attached to
			 the conical sedimentation with an
			inbuilt spoon
		 (b) The sedimentation cone scoop of
			 fecal specimen is assembled to
			 the mixing chamber and then
			 vortexed with the sedimentation cone
			facing upward
		 (c) Tube is then centrifuged after
			 inverting at 400 g for 2 min
		 (d) Sedimentation chamber after
			centrifugation
		 (e) Wet mount preparation from the
			sediment
b.
		
		
		
		
		
		
		
		
		

Trichrome stained fixed smear:
It is a rapid and simple procedure, which
produces uniformly well-stained smears of
the intestinal protozoa and differentiate from
human cells, yeast, and artifact material on
ethanol fixed fecal smears. The main
advantage is the visual clarity of the internal
structure of ova, cysts and trophozoites of
enteric protozoa fresh and polyvinyl alcohol
fixed specimen (Figure 2).
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Figure 4: cellophane (scotch) tape collection and preparation method

2. Fecal Culture and Sensitivity
Figure 2: Trichrome stain Giardia lamblia (100 X)

c. Modified Acid-Fast fixed smear:
		 It is also a simple, rapid and effective staining
		 procedure for the identification of oocysts of
		 coccidian species (cryptosporidium
		 and cyclospora). It can be used on fresh or
		 formalin fixed fecal specimen and duodenal
		 fluid. Immunocompromised population with
		 chronic diarrhea must get evaluated by
		 special request of modified acid-fast stain
		(Figure 3).

Figure 3: Cryptosporidium: Modified acid-fast stain under oil immersion
(100 X)

d. Cellophane (Scotch) tape preparation:
		 This is used to identify the pin worm
		(Enterobius vermicularis) and their ova
		 around perianal area where female worm
		 lays their eggs at night. Fecal specimen is not
		 appropriate method for identify pin
		 worm. After placing scotch tape on glass
		 slide for microscopic evaluation is performed.
		 For better yield, three consecutive morning
		 sample is recommended (Figure 4).

It is usually set for isolation and identification
of epidemiologically significant enteric bacterial
pathogens including Salmonella species, Shigella
species, Campylobacter species, Aeromonas
species and Vibrio species on fresh fecal or stored
and transported fecal specimen in Clary-Blair
medium. Rectal swabs can be used in those who
has difficulty in specimen collection. Below is the
rectal swab collection procedure:
m Pass the tip of a sterile swab
		 approximately one in. beyond the anal
		sphincter.
m Carefully rotate the swab to sample the
		 anal crypts, and withdraw the swab.
m Send the swab in Cary-Blair medium or
		 buffered glycerol saline.
Specimen submission during the acute stage of
infection (usually five to seven days) is essential
because pathogens decrease in number with time.
If fresh stool is submitted for culture that is not in
transport medium, the specimen
should be transported to
laboratory and processed within
two hour after collection. For
best recovery in cases for delay
of < 24 hours, refrigerate at 4°C.
If the initial stool culture is
negative, then additional fecal
samples may be submitted for
testing from different defecations
on successive days (Figure 5).
Figure 5: Clary-Blair transport medium for fecal specimens

9
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3. Enzyme Immunoassays (EIA)
This method is helpful for detection of fecal
antigen, and toxin. The available tests are for

Entamoeba histolytica, Clostridium difficile,
Giardia lamblia, Helicobacter pylori, Rotavirus
and adenovirus.
Substrate
Enzyme-labeled
avidin

Substrate
Enzyme-labeled
antivirus
antibody

Biotin-labeled
antibody

Specimen
(virus)

Specimen
(virus)

Antivirus
antibody

Antivirus
antibody

Figure 6: Enzyme-linked immunosorbent assay (ELISA) for detection of virus and/or viral antigen. Left, direct. Right, avidin–biotin.

4. Multipanel Nucleic acid amplification test
(NAT)
This PCR base technology works on syndromic
approach and utilize multiple nucleic acid
Bacteria

Virus

sequences or gene targets of diarrhea causing
agents in a single test run with in span of an hour.
Therefore, the test is rapid and specific. Below
is the list of causative organisms that can be
detected
Protozoa

n

Clostridium difficile

n

Adenovirus F 40/41

n

Cryptosporidium

n

Shiga-toxigenic E. coli (STEC) 0157

n

Astrovirus

n

Cyclospora

n

Shiga-toxigenic E. coli non-O157

n

Norovirus GI/GIl

n

Enterotoxigenic E. coli (ETEC)

n

Rotavirus A

n

Entamoeba histolytica

n

Enteropathogenic E. coli (EPEC)

n

Sapovirus

n

Giardia lamblia

n

Enteroinvasive E. coli (EIEC)/
Shigella

n

Enteroaggregative E. coli (EAEC)

n

Salmonella

n

Plesiomonas shigelloides

n

Aeromonas

n

Vibrio

n

Vibrio cholerae

n

Campylobacter

n

Yersinia enterocolitica

10
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The FilmArray Pouch
Sample
Injection
Port

DNA/RNA
Purification

PCR I

PCR II

Cell
Lysis

Water
Injection
Port

Dilute 100x

PCR I

PCR II

Figure 7: FilmArray multiplex nested PCR for detection and identification of several causative agents.

The conventional laboratory diagnostic tools for
gastrointestinal tract infection can be effective
for parasites, few bacteria and viruses, however,
the detection ability is dependent strongly upon
laboratory quality assurance processes and
competence of technologist.

For improve patient’s outcomes, it is now
imperative for health care facilities to be abreast
with the evolving diagnostic facilities for example
syndrome based multiplex nested PCR that can
have long lasting health care impact.

Pleuropulmonary Blastoma Type III with
Rhabdomyosarcomatous and Chondrsarcomatous
Differentiation in a Five year old Child, A Rare Case.
Dr Saman Muhammad Amin and Dr Sabeeh Uddin Siddique
Histopathology

Introduction
Pleuropulmonary Blastoma is a very rare malignant
tumor of infancy and early childhood arising as

a cystic and/or solid sarcomatous neoplasm in
the lung or (rarely) the pleura. This embryonic
or dysontogenetic neoplasm is the counterpart of
neuroblastoma, hepatoblastoma, retinonblastoma
11
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and Wilms tumor. Pleuropulmonary Blastoma
tumors are subgrouped as type I (purely cystic),
type II (solid and cystic) and type III (purely
solid).
Case Presentation
A five years old boy presented with mediastinal
mass. Patient had been initially diagnosed as “Mixed
germ cell tumor” from outside AKUH and had
been treated accordingly. We received the specimen
coded as “Right lung upper lobe and mediastinal
mass” and it consisted of a single lobe of lung with
a protruding cystic mass that was already ruptured
and a separately lying piece of mass. The mass had
lobulated appearance. On sectioning the cut surface
appeared whitish and glistening.
Microscopic examination of this mass revealed a
neoplastic lesion comprising of multicystic structures
that were lined by respiratory type epithelium and
underlying sheets of small primitive malignant
cells showing a cambium layer like zone. Blastemal
cells were present along with sheets of markedly
pleomorphic cells that showed abundant eosinophilic
cytoplasm and relatively eccentrically placed
hyperchromatic nuclei and variably conspicuous
nucleoli (Rhabdomyoblastic differentiation) (Figures 1
and 2). Abundant lobules of neoplastic cartilage were
also identified that showed mild to moderate nuclear
atypia and increased cellularity. Fascicles of atypical
spindle shaped cells are also identified. Brisk mitoses
including atypical mitoses, necrosis (approximately
20 percent), hemorrhage, fibrosis and dead bone are
appreciated. Immunohistochemical stains Desmin
and Myogenin highlights rhabdomyoblastic cells
and Cytokeratin AE1/AE3 and TTF-1 highlights
native respiratory epithelium. The case was
diagnosed as Pleuropulmonary Blastoma, type III

12

Figure 1 Rhabdomyoblastic differentiation.

Figure 2 Pleuropulonary blastoma. Cystic structure lined by epithelium.
A nodule of cartilage is present in cyst wall along with rhabdomyoblasts.

(Rhabdomyosarcomatous and chondrosarcomatous
differentiation).
Conclusion
Pleuropulmonary Blastoma is a rare tumor and it
should always be considered in the differentials
when evaluating small lung biopsies taken
from children that exhibit cartilaginous and
mesenchymal components.
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New and Emerging Paediatric Bone and
Soft Tissue Tumors: An Update from the 5th
Edition of WHO Blue Book
Dr. Qurratulain Chundriger and Dr. Nasir Ud Din
Histopathology

With the ongoing advances in molecular techniques
new knowledge about molecular mechanisms
behind etio-pathogenesis of neoplastic processes is
continuously being acquired. The result is a havoc in
the fields of pathology and pharmaceutical industry,
because in addition to the identification of novel
mutations reclassifying certain tumors as specific
entities, traditionally being put under umbrella terms
and waste basket diagnoses, specific therapeutic targets
are being recognized and drugs are being developed
by the truck load. Welcome to the era of personalized
medicine!
The fifth edition of the WHO classification of
Tumors of Bone and Soft tissue was recently
published, seven years after the 4th edition. In
addition to a different and more reader friendly
pattern of the volume on the whole, a useful addition
are the headings of Essential and desirable
diagnostic criteria, Cytological features, revised
Staging and evidence-based discussion under the
heading Prognosis and Prediction. Furthermore,
a number of new and emerging entities have been
added to this edition, few of which arise mostly in
the adult population, few solely in the paediatric
patients and some show overlap and a wide age range
from infants to the elderly. This article focuses not
only on the paediatric tumors but those with a wide
age range have also been discussed as they may
also be encountered in patients less than 18 years of
age. Some of these tumors have been established as
entities while a few are still emerging with ongoing
clinical, morphological, phenotypic and molecular
studies.
Poorly Differentiated Chordoma (PDC)
PDC arises in children, more commonly females, with
a mean age of 11 years. Axial skeleton, specifically
skull base is the most commonly involved site. Clinical

presentation is with headache and symptoms of cranial
nerve compression.
Radiology shows origin and destruction of bone, with
infiltration into the adjacent soft tissue. Heterogeneous
appearance is seen on CT and MRI.
Histologically, the most striking features is absence
of the physaliphorous cells typical of Chordoma.
The myxoid background stroma may be only focally
present. The tumor is composed of epithelioid cells,
growing in cohesive nests and sheets with abundant
eosinophilic “pink” cytoplasm. Cytoplasmic vacuoles
may be seen, imparting signet ring like features. The
nuclei are pleomorphic, round to oval with vesicular
chromatin. Numerous mitoses and necrosis are
generally present (Figure 1).

Figure 1. H&E stained sections show sheets of epithelioid cells with
distinct cell borders and cytoplasmic vacuoles.

Immunohistochemically, positive expression of
Cytokeratins and Brachyury, but the expression of S100
is variable. An essential diagnostic feature is the loss
of nuclear INI-1, which results from deletion of the
13
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SMARCB1 gene. Fluorescent in-situ hybridization is
the method to evaluate this along with co-deletion of
EWSR1 locus. This tumor shows worse prognosis as
compared to Chordoma.
BCOR Family of Tumors
This entity comprises of a group of round cell
sarcomas, sharing clinical and morphological features
with other round blue cell soft tissue sarcomas like
Ewing Sarcoma. Before the identification of BCOR
gene mutations these tumors were grouped under the
heading of undifferentiated round cell sarcomas.
The BCOR gene shows several types of alterations,
resulting in a group of tumors which either show
rearrangements and fusion with other genes – BCORCCNB3 most frequently – or have internal tandem
duplications – BCOR-ITD. The former group belongs
to patients less than 20 years of age; while, the latter
along with Primitive Myxoid Mesenchymal Tumor
of infancy typically arises in infants. Whatever the
mechanism, the end result is oncogenic activation
of the BCOR gene along with overexpression,
identification of which aids in the diagnosis.
Bones of pelvis, lower extremities and paraspinal
region are the usual sites of origin for BCOR-CCNB3
sarcomas. Although they may arise less frequently in
soft tissue sites as well for example lung, head and neck
region and kidney. BCOR-ITD and Primitive Myxoid
Mesenchymal Tumor of infancy mostly occur in soft
tissues of trunk, retroperitoneum and head and neck
region.
Patients present with pain and swelling. Grossly the
tumor may grow to large sizes of more than 10 cm.
Microscopically, the distinctive feature in addition to
the round cell morphology is the presence of a rich
capillary network, which if growing in kidney, may
mimic Clear Cell Sarcoma in an infant. The tumor
cells have finely dispersed chromatin. Some tumors
may exhibit spindle cell morphology mimicking a
Synovial Sarcoma and a myxoid background. Strong
nuclear expression of BCOR on immunohistochemistry
is the most important marker for diagnosis along with
expression of SATB2 and Cyclin D1, regardless of the
mechanism of BCOR gene alteration.
14
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These tumors also sometimes harbor YWHAENUTM2B fusions, as seen in High grade Endometrial
Stromal Sarcomas and Clear cell Sarcoma of kidney.
This fusion also results in oncogenic activation of the
BCOR gene and nuclear BCOR expression. Cyclin
B3 is additionally expressed by the BCOR-CCNB3
sarcomas.
Lung is the most common site for metastatic disease.
The chemotherapy regimen and five-year survival rates
for BCOR-CCNB3 sarcomas is similar to that of Ewing
Sarcoma. Data on other BCOR family sarcomas is still
not clear.

Figure 2. H&E stained section showed round and spindle cells in a
BCOR rearranged sarcoma.

CIC Sarcomas
These are high grade round cell sarcomas showing
rearrangements of CIC (Capicua Transcriptional
repressor) gene, with several fusion partners, DUX4
being the most common. They were previously
grouped under the umbrella of undifferentiated round
cell sarcomas along with BCOR family of tumors and
represent the most frequent subtype of ‘Ewing-like
tumors.
These tumors mostly arise in adolescents with a mean
age of 25-25 years although a substantial number is
seen in paediatric patients as well. Deep soft tissues of
extremities and trunk are the common sites of origin
with head and neck region being less common, similar
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to the BCOR tumor family. Presentation with mass
lesion with or without pain is common, as is initial
presentation with metastatic disease.
These tumors tend to be large with frequent necrosis
and hemorrhage. Microscopic examination shows
lobulated growth with indistinct fibrous stroma.
Sheets of undifferentiated round cells with admixed
minor population of epithelioid or spindle cells is
seen (Figure 3). In contrast to the more common
Ewing Sarcoma, CIC rearranged sarcomas exhibit
nuclear pleomorphism with open chromatin and
variably prominent nucleoli. Mitotic activity is brisk.
These tumors express CD99 in a patchy distribution
as compared to diffuse membranous staining seen
in Ewing Sarcoma. NKX2-2, a marker for Ewing
Sarcoma, is also negative. WT-1 and ETV4 are also
expressed consistent and constitute the criteria for
diagnosis along with molecular evidence of CIC
mutations.

Figure 3. H&E stained sections showing variable appearance of
epithelioid to round to spindle cells

CIC-DUX4 fusion is the most common alteration
seen in more than 95 percent of cases, which results
from either t(4;19)(q35;q13) or t(10;19)(q26;q13)
translocations. Other rarer fusion partners include
FOX04, LEUTX, NUTM1 and NUTM2A.
Most of these tumors behave aggressively with
metastatic disease, lung being the most common site.
The response to Ewing Sarcoma chemotherapy is not
good and the five-year survival rates are also far worse.
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NTRK-Rearranged Spindle Cell Neoplasm
The WHO defines this group as an emerging group
of molecularly defined rare soft tissue tumors
showing a wide spectrum of morphological features
and coexpressing S100 and CD34. It is a provisional
category and includes Lipofibromatosis-like neural
tumors and tumors that closely resemble peripheral
nerve sheath tumors. Most of these occur in
patients less than twenty years of age, with the
latter two seen most in children. They arise in the
extremities and trunk as either superficial or deep
tumors.
Microscopically they exhibit a wide range
of morphology, at one end of which is
Lipofibromatosis-like neural tumor and at the other
end are tumors resembling Malignant Peripheral
Nerve sheath tumor. The former group shows a
highly infiltrative pattern of growth comprising
of spindle cells with bland appearance, having
indistinct cytoplasm and tapering nuclei. Mild
nuclear atypia and more cellular examples may be
sometimes seen. Necrosis is absent and mitosis is
only scant. The latter group comprises of spindle
cell tumors exhibiting solid growth, high cellularity
and prominent stromal bands and perivascular
keloid like collagen deposition, which is hallmark of
these tumors. Although the cells are monomorphic,
the growth pattern with streaming bands and
patternless areas is typical. A variable mixture of
these two appearances may also be seen with some
less cellular areas merging with more cellular foci.
Some examples may show nuclear pleomorphism
and high mitotic activity with necrosis. A smaller
subgroup with NTRK-1 rearrangements shows
myopericytoma-like morphology.
S100 and CD34 positivity is the rule, with absent
SOX10 staining and retained H3K27me3 expression,
which helps in differentiation from MPNST. Majority
of them show positive nuclear or cytoplasmic staining
with anti-Pan-TRK monoclonal antibody, a nonspecific marker for NTRK gene rearrangement.
Additional testing is required for conclusive diagnosis
and deciding the appropriate therapy depending on the
fusion partner.
15
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Prognosis is grade dependent. The lower grade
lesions have a propensity for local recurrence
due to infiltrative growth, while the higher-grade
lesions exhibit an aggressive course with metastasis
most commonly to lungs. Targeted therapy against
receptor tyrosine kinases (TRKs) has a role in the
treatment of these patients.
EBV-Associated Smooth Muscle Tumor
This entity arises in the setting of immune
deficiency in one of three settings in descending
order: 1- HIV/AIDS 2- after solid organ or
hematopoietic stem cell transplant and 3congenital or primary immunodeficiency. Children
are the most affected population in cases of
primary immunodeficiency, the other scenarios
being common in adults. The latent period after the
onset of immunodeficiency is long, spanning up
to several years. If encountered outside the three
described scenarios, the patient should be worked
up for immunodeficiency.
These tumors can arise at any site in the body
including solid organs. The most reported in
CNS (intra and extra-axial). They can reach
large sizes of more than twenty cm. Cut surface
is rubbery and firm consistency. Microscopic
examination shows typical morphology of smooth
muscle tumors, having interconnected fascicles
of spindle cells with eosinophilic cytoplasm and
uniform elongated nuclei. The distinctive features
of EBV associated tumors is the presence of
small round primitive appearing smooth muscle
cells and a variable infiltrate of T lymphocytes
within the tumor, the latter being more common
in the setting of HIV infection. Some tumors
may exhibit hemangiopericytoma-like blood
vessels. Immunohistochemistry shows positivity
for Smooth muscle Actin and H-Caldesmon with
patchy variable Desmin. EBER is consistently
positive on In-situ hybridization and is required
for diagnosis. Prognosis is largely dependent
on the individuals’ overall condition. Most
of these tumors do not metastasize and some
have been shown to regress on reduction of
immunosuppression.
16
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Myxoid Pleomorphic Liposarcoma
It is a highly aggressive and extremely rare
adipocytic tumor, most commonly occurring in
children and young adults. It shows features of both
Myxoid Liposarcoma and Pleomorphic Liposarcoma
but lacks the genetic alterations of Myxoid
Liposarcoma, Dedifferentiated Liposarcoma and
Atypical Lipomatous Tumor. Deep soft tissues of
mediastinum is the most common site of origin.
Histologically, these tumors show a mixture
of appearances with areas having delicate
curvilinear vascular network, myxoid background
with lipoblasts and bland primitive round cells
reminiscent of conventional myxoid liposarcoma.
There is gradual transition to more cellular
areas with presence of more pleomorphic
lipoblasts, necrosis, numerous mitoses and
severe nuclear atypia. They have a non-specific
immunophenotype.
Diagnosis requires absence of FUS/EWSR1DDIT3 gene fusions of Myxoid Liposarcoma and
MDM2 amplifications of well-differentiated/
Dedifferentiated Liposarcoma. Myxoid Pleomorphic
Liposarcoma has aggressive clinical course with
frequent metastases and poor survival.
EWSR1-SMAD3-Positive Fibroblastic Tumor
This entity is defined as a benign spindle cell
tumor occurring in superficial tissues of hands
and feet. A wide age range is described (one-sixty
eight years). The tumor is small and painless,
up to 1-2 cm in size. This tumor is usually wellcircumscribed. Microscopically there is zonation,
with fascicles of spindle cells growing at the
periphery of the nodule, while the center is less
cellular and often hyalinized. The spindle cells
have a bland appearance and lack significant
nuclear pleomorphism, mitotic activity or necrosis.
ERG expression by immunohistochemistry is the
rule, along with negative SMA and CD34. EWSR1SMAD3 fusion is the defining genetic abnormality.
Complete excision is curative with rare instances of
local recurrence.
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Radiology Pathology Correlation: Orthopedic
Pathology
Nasir Ud Din and Dawar Khan
Pathology and Radiology

A three year old male child presented with headache.
X-ray was done which showed multiple punched out
lytic lesions (Figure 1)

Figure 1. X-ray head lateral view showing multiple punched out lytic
lesions, beveled margins and without sclerotic margins.

A biopsy of skull bone was done which histologically
showed fragments of bone infiltrated by a neoplastic
process composed of sheets of ovoid cells with
nuclear grooves, irregular nuclear membranes and
eosinophilic cytoplasm. Scattered osteoclast-like giant
cells were noted. In the background, eosinophils,
neutrophils and lymphocytes were seen. The
neoplastic cells were positive for CD1a, S100 and
CD68. A diagnosis of Langerhans cell histiocytosis
was rendered after radiology-pathology correlation.

Discussion
Langerhans cell histiocytosis (LCH) also known
as eosinophilic granuloma, is a clonal proliferation
of Langerhans cells. Langerhans cells regulate the
immune system and normally found throughout the
body, especially in the skin, lymph nodes, spleen, lungs,
liver, and bone marrow. The disease usually diagnosed
during the first three decades of life. The disease can be
unifocal or multifocal. It commonly involves skeleton
(skull>femur>pelvis>ribs). Monostotic form is more
common than polyostotic. Skin, lymph node and lung are
other common sites on involvement. In bone, it comprises
<1 percent of all bone tumors. Clinical symptoms depend
on the site involved. Radiographically, in long bones,
present usually as well-defined lytic lesions, but may have
ill-defined margins. In skull (50 percent involvement) it
appears as discretely punched out lesions involving tables
of skull unevenly resulting in beveled edges. Radiological
differential diagnosis include osteomyelitis, metastasis,
primary bone tumor, lymphoma and leukemia.
In the affected organs, there infiltration of Langerhans
cells, accompanied by a variable admixture of
eosinophils, giant cells, neutrophils, and foamy cells.
The Langerhans cell express CD1a, CD207 (langerin),
S100 and CD68 immunohistochemical stains.
Histologic differential diagnoses include osteomyelitis,
granulomatous inflammation, chondroblastoma,
Hodgkin lymphoma and Rosai-Dorfman’s disease.
LCH is differentiated from osteomyelitis by ovoid cells
with grooved nuclei and CD1a
positivity. Chondroblastoma
contain polygonal cells with
nuclear grooves and S100
positive, but negative for CD1a
and preferentially involves
epiphysis of long bones.

Figure 2. A) H&E showed sheets of Langerhans cells with scattered osteoclast-like giant cells. B) CD1a
positivity in Langerhans cells

Monostotic skeletal
involvement has excellent
prognosis. Multifocal disease
has guarded prognosis.
17

MAY 2021

VOL 46, ISSUE 3

High Performance Liquid Chromatography for
Hemoglobin Variants Analysis in Paediatric
Population
Dr Natasha Ali, Dr Hajrah Syndeed and Dr Asif Naveed
Haematology

Hemoglobin
Hemoglobin (Hb) is an iron binding protein that not
only transports oxygen but also body’s respiratory
carbon dioxide. The red colour of cells (hence the
name) is due to this protein.
There are four subunits of Hb each having one
polypeptide chain and one heme group. The heme
group has iron protoporphyrin IX associated with
a polypeptide chain of 141(α) or 146 (β) amino acid
residues. The adult Hb has two types of polypeptide
chains known as alpha and beta chains. Both
embryonic and adult Hb have similar alpha chains.
The other (non-alpha chains) include the beta chain of
normal adult Hb (α2β2), the gamma chain of fetal Hb
(α2β2), and the delta chain of HbA2.
Normal hemoglobin types include:
• Hemoglobin A: 95-98 percent of Hb found in
		 adults comprises of HbA; it’s a combination
		 of two alpha and two beta protein chains.
• Hemoglobin A2: Adults have only 2-3 		
		 percent of HbA2 comprising two alpha and
		 two delta protein chains.
• Hemoglobin F (fetal hemoglobin): It is the
		 major Hb found in fetal stage whereas makes
		 up to 1-2 percent of Hb found in adults. It is
		 composed of two alpha and two gamma
		 protein chains. HbF is replaced by HbA by
		 one-two years of age.
Mutations in Hb
Hemoglobinopathy is defined as genetic
defect that results in abnormal structure of
one of the globin chains of the Hb molecule.
Hemoglobinopathies are generally single gene
defects inherited as a dominant trait in majority of
cases.
18

As a result of mutations in the globin genes
there could be either a quantitative reduction in
production of Hb or a qualitative defect in the
protein produced. Quantitative defects lead to
development of thalassemia, whereas qualitative
defects, also called Hb variants, result in a wide
range of diseases including sickle cell disease,
unstable Hb, decreased oxygen affinity, increased
oxygen affinity and methemoglobinemia. Pakistan
being a resource constrained country and where
consanguineous marriages are commonly practiced,
is a victim to a huge number of patients suffering
from hemoglobinopathies. This pose a massive health
problem. In one recent study, the estimated frequency
reported was 34.2 percent. Another estimate states
that a total of 5000–9000 children with β-thalassemia
are born per year, although no documented registry is
available in Pakistan. An approximate carrier rate is
five–seven percent, with projected 9.8 million carriers
in our total population.
Indications for Testing
1. Complete blood count shows RBC indices 		
suggestive of thalassemia trait and/or blood smear
shows features of an abnormal hemoglobin.
2. Presenting signs and symptoms in a child
suggestive of severe anemia and/or failure to
thrive such marked shortness of breath, weakness,
lethargy, pale skin, abnormal bossing of facial
bones and splenomegaly.
3. Episodes of pain in chest, hands and feet, ulcers
formation on bony surfaces (suggesting a specific
form of abnormal Hb i.e. sickle cell disease).
4. Family history of hemoglobin disorders; as part of
family screening.
5. Prenatal screening in a pregnant female:
when either of the parent is high risk or there is
a diagnosed/suspected thalassemic child

MAY 2021

VOL 46, ISSUE 3

previously born to the couple.
6. As a part of state legislation for neonatal
screening programs, where indicated.
Sample
Venous sample stored in EDTA tube is required for
testing. In neonates/infants, a finger stick/heel stick
(samples taken by pricking the finger or heel of the
neonate) sample may be collected due to difficult
phlebotomy and low blood volume in neonates.
Pretesting special preparation is not required, however
results of blood transfusion interfere with proper
interpretation of test. A pre-transfusion sample should
be preferably sent in cases requiring transfusion.
Principal of High Performance Liquid
Chromatography (HPLC)

according to the dictionary of the instrument.
HPLC leads to separation as well as quantification of
HbF and HbA2. It also detects variant hemoglobins
(sickle cell Hb, Hb C, HbD, HbE) along with
thalassemia.
HPLC is equally capable for identifying
hemoglobinopathies from both newborns/paediatric
and adult populations and takes the benefit of the
algorithm/software/instrument specification.
Interpretation of Results
The report provides the presence of normal as well as
vairant hemoglobins in order of their quantification.
Along with pathologist review, the results are
interpreted in close relation with patient’s sign and
symptoms and family history.

HPLC forms one of important tools for testing for
The following table provides some examples of test
hemoglobinopathies. Different types of hemoglobins
interpretation: (This table suggests the role of genetic
are separated based upon the ionic charges they
mutation contributing towards the pathogenesis: final
carry. An analytical cation exchange cartridge uses
conclusion requires genetic studies).
a preprogrammed buffer gradient. The hemosylate
Heterozygous: One gene copy for variant Hemoglobin
passes through the cartridge and separates hemoglobin
Homozygous: Two gene copies for variant Hemoglobin
fractions upon interaction
Results seen
Condition
Possible Genetic Pathology
with resin. There’s a flow
Hb A: 50-65 percent
Sickle cell trait
Heterozygous for HbS
cell where absorbance is
Hb S: Up to 45 percent
measured at 415 nm and
Hb S: More than 80 percent
Sickle cell disease
Homozygous for HbS
again at 690 nm to reduce
Hb F: 2-20 percent
background noise. Separated Hb A: Absent
fractions pass through this
Hb C: More than 80 percent
Hemoglobin C disease
Homozygous for HbC
flow cell. Changes produced
Hb A: Absent
in absorbance due to passage
Hb F: More than 80 percent
Beta thalassemia major
Both beta genes mutated
of fractions of hemoglobins
Hb A: Present in small amount or
are measured and recorded
completely absent
over time producing a
Hb A: More than 80 percent
Beta thalassemia minor/ Beta Mutations in one beta gene
chromatogram (absorbance
Hb A2: Increased (4-8 percent)
thalassemia trait
leading to decrease production
Hb F: Usually increased slightly
from one beta globin chain
vs. time).
as compared to reference values

Each type of hemoglobin has
a specific retention time which is characteristic to it,
hence leading to its identification. This retention time
is measured from the time of sample is injected into
the HPLC to the highest point achieved by each peak.
This peak determines the maximum elution for that
type. While assessment, there can be other peaks in
the chromatogram which are labeled as Unknown.
These peaks are due to hemoglobin fractions that
elute at a retention time which is not pre-programmed

Conclusion
HPLC forms a reliable method for both diagnosis as
well as screening for suspected hemoglobinopathy in
paediatric population. It is a simple technique which is
highly reproducible with automation, high resolution
and rapid results with a short turnaround time thus
facilitating patient and physicians. The definitive
diagnosis may require genetic testing in small fraction
of patients only.
19
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Updates in Reporting Wilms Tumor
(Nephrectomy) Specimen
Dr Qurratulain Chundriger, Dr. Zoonish Ashfaq and Dr Nasir-Ud-Din
Histopathology

Paediatric medicine has changed a lot since the advent
of more advanced molecular diagnostic techniques
and neo-adjuvant therapy. This is particularly true for
solid paediatric tumors. Talking about renal tumors, in
contrast to getting a resection specimen for primary
diagnosis, more and more patients are being first
treated with neo-adjuvant chemotherapy followed
by surgical resection. This has resulted in refined
and revised guidelines for reporting and treatment.
Wilm’s tumor is one of the most commonly occurring
malignant paediatric renal tumors in children up to
six years of age. The most common presentation is a
mass felt in the abdomen, mostly by the mother. Some
cases of presenting with tumor rupture have also
been reported. Radiologically it presents as a solid
mass in the kidney with sometimes associated foci of
calcifications. In certain parts of the world including
south Asia, pre-operative chemotherapy has become
standard in Wilms tumor patients.
In this article, we will review the parameters for
reporting of post chemotherapy nephrectomy
specimen and their implications in further treatment of
patients.
Wilms Tumor
Nephroblastoma or Wilms tumor is the most commonly
encountered surgical pathology specimen in the
histopathology lab with status-post chemotherapy
resection. The guidelines for reporting the changes

secondary to chemotherapy have evolved over the
years. The WHO blue book for renal tumors discusses
two groups of thoughts in this regard. The two main
stakeholders are the Children’s’ oncology group (COG)
and Society of Paediatric Oncology (SIOP). The
COG advocates initial resection of tumor, followed
by therapy, based on histological findings of grade
and stage, while the SIOP applies to resection after
the administration of neo-adjuvant Chemotherapy.
Under COG, only special circumstances allow for the
administration of pre-operative therapy which include
Congenital solitary kidney, inoperable tumor, bilateral
tumors, vena caval tumor thrombus above the level of
hepatic vein, direct extension into adjacent structures
like pancreas, spleen colon and presence of extensive
metastases in the lung.
Post chemotherapy resection provides the advantage of
tumor shrinkage, less instances of per-operative rupture
and hence stratification into lower stage group. The
SIOP guidelines for these specimen help in deciding
the next step in management. While the COG takes
into account the tumor biology and chooses the therapy
regimen and protocol based on the primary appearance
and histology of the tumor. Both groups have shown
more or less similar outcomes in terms of disease
stratification according to stage and overall survival.
The following table highlights differences in COG and
SIOP staging systems, as described by the WHO blue
book (bold text):

Stage

COG

I

Tumor limited to kidney (may show minimal infiltration of
renal sinus soft tissue but without vascular invasion) and
completely resected

Tumor limited to kidney without any infiltration of renal
sinus soft tissue. Presence of necrotic tumor outside these
parameters does not upstage it.

II

Tumor extends beyond kidney (renal capsule invasion,
lymphovascular invasion, renal vein invasion with negative
renal vein margin and renal sinus fat invasion) but is
completely resected with negative surgical margins

Tumor extends beyond kidney (renal capsule invasion,
lymphovascular invasion, renal vein invasion with negative
renal vein margin and renal sinus fat invasion) but is completely
resected with negative surgical margins
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III

Residual tumor (positive margins, rupture, surgical spill,
Residual tumor (positive margins, rupture, surgical spill,
positive nodes, piecemeal excision and pre-operative biopsy) positive nodes, piecemeal excision and necrotic tumor or
chemotherapy-induced changes at resection margins or in
lymph nodes)

IV

Metastasis (hematogenous or lymph node beyond the renal
drainage system, i.e. outside abdomino-pelvic region)

V

Bilateral renal involvement on initial diagnosis (both kidneys Bilateral renal involvement on initial diagnosis (both kidneys to
to be staged separately)
be staged separately)

Post-operative Chemotherapy
These changes in the staging system are significant
for choosing the next step in patient treatment. Postsurgical therapy is a routine according to COG except
in patients who are less than two years at diagnosis,
favorable tumor histology tumor of less than 550 gms,
stage I as defined above with negative lymph nodes.
Similarly, SIOP also recommends post resection
chemotherapy in all patients except those with Stage I
disease and low risk tumors.
Post-operative Radiation
COG: recommends radiating the tumor bed in stage
III disease.
SIOP: recommends radiating the entire abdomen in
patients with high risk histology, tumor rupture or
peritoneal deposits. The importance of favorable or
unfavorable histology also comes into account when
decision for including the lungs in radiation field
needs to be taken.
Reporting of surgical pathology specimen:
Gross Observations of Intact Specimen
The following points are mandatory for synoptic
reporting of gross (and microscopic) findings:
- Intactness of Gerota’s fascia is an important
		 parameter in staging the tumor
- Status of renal capsule
- Weight of the specimen
- Tumor focality
- Size of the tumor
- Presence of renal sinus involvement grossly
		and microscopically
- Involvement of Renal vein with mention of
		resection margins
- Involvement of adjacent organs if present in
		 the resection specimen
- Status of resection margins

Metastasis (hematogenous or lymph node beyond the renal
drainage system, i.e. outside abdomino-pelvic region)

Following parameters can be assessed exclusively on
histological examination:
- Histologic type – define histology (favorable,
focal anaplasia, diffuse anaplasia)
- Post-therapy histologic classification
Anaplasia in Wilms Tumor
The WHO defines Anaplasia as “Cells with huge
hyperchromatic nuclei associated with multipolar
mitotic figures”. To classify as anaplastic, the largest
dimension of these nuclei should be more than three
times the largest dimension of tumor cell nuclei in
other areas. Atypical mitotic figures are larger than
normal mitoses and exhibit more than two poles.
Another term worthy of mentioning is “Severe
nuclear unrest” which is defined as severe nuclear
atypia approaching the criteria of anaplasia but not
meeting the criteria.
Focal anaplasia is presence of 1 or few sharply
outlined tiny foci of anaplasia within the intrarenal
tumor. The remaining tumor must not exhibit severe
nuclear unrest.
Diffuse anaplasia is the presence of any amount
of anaplasia in any of the extrarenal sites i.e. renal
sinus, lymphatic/vascular channels, extra capsular
tumor deposits, lymph nodes or other metastatic
sites. Presence of any anaplasia, albeit a single cell
or a single atypical mitotic figure in a random biopsy
qualifies for diffuse anaplasia.
Post-Therapy Histologic Classification
Chemotherapy-induced changes include necrosis,
xanthomatous histiocytic foci, hemosiderin deposits
and fibrosis. Chemotherapy-induced maturation may
also be seen in some instances. The most commonly
seen pattern of differentiation is skeletal muscle. Postchemotherapy histologic findings are used to classify
patients into groups with low, intermediate or high
21
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risks of poor survival and aggressive behavior of the
disease.
The categories outlined by the COG and SIOP apply
only to Wilms tumor with favorable histology. These
categories are based on quantifying the proportion
of viable, blastemal tumor. The staging for post
therapy nephrectomy specimens differs only in the
interpretation of areas of necrosis outside the kidney.
The presence of necrotic tumor or chemotherapyRisk Stratification

induced changes in a lymph node or at the resection
margins is regarded as proof of previous tumor with
potential microscopic residual disease, and therefore
the tumor is assigned stage III. The overall idea is
tumors with most of the tumor being viable and
composed of Blastema after chemotherapy is going
to behave more aggressively. The following table
explains the risk groups based on the amount of viable
tumor with the proportion of Blastema. Also refer to
Figures 1 and 2 for histologic appearance of tumor.
Parameters

Low risk

No viable tumor. Residual nephrogenic rests may be seen

Intermediate risk

Viable tumor, <33 percent of the mass regardless of histology
Viable tumor, >33 percent of the mass, with <66 percent Blastemal histology in viable areas

High risk

Viable tumor, >33 percent of the mass, with >66 percent Blastemal histology in viable areas

Reference: https://documents.cap.org/protocols/cp-paediatric-wilms-biopsy-19-4000.pdf

Figure 1 This image shows a few residual tubules surrounded by a zone
of fibrosis and hemorrhage with scattered inflammatory cells (taken from
webpathology.com).

Conclusion
Paediatric renal neoplasms are being studied in
the context of molecular testing with the aim
of developing targeted and more sophisticated
therapeutic options. Our understanding of the
biological mechanisms underlying pathogenesis
and potential for aggressive behavior are evolving.
This area of cell biology and cancer genomics
22

Figure 2 Few residual nodules of blastema and scattered tubular
elements. Post-chemotherapy specimens in which blastemal component
constitutes more than 2/3 of the viable tumor are considered high risk
tumors (taken from webpathology.com).

is definitely going to see a huge growth in
the upcoming years, with the advent of newer
drugs like immunotherapeutic agents recently
developed for a number of solid tumors. Our
aim as physicians and health care providers is to
provide the best therapeutic options catered to
the individual patients’ needs and reporting of all
the parameters which will help and guide in this
regard.
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Biotinidase Deficiency- a Rare but Treatable
Disorder
Dr Sibtain Ahmed
Chemical Pathology

Biotin, widely known as hair and skin vitamin, is a
water-soluble vitamin present in small amount in various
foods. It is recycled in the biotin cycle by the action
of the enzyme Biotinidase a glycoprotein detectable
in dried blood spots, serum, leukocytes, fibroblasts,
and hepatocytes. Biotinidase Deficiency (BD), is an
inherited autosomal recessive disorder caused by
absent or markedly deficient activity of the enzyme
biotinidase. As biotin serves as the cofactor of the four
human carboxylases, BD results in multiple carboxylase
deficiency, a potentially life-threatening disorder with
impairment of gluconeogenesis and organic acids
metabolism.
The incidence of BD is 1:40,000 to 1:60,000 births in the
world; however, in countries with higher consanguinity
rate, such as the United Arab Emirates and Turkey,
the frequency is significantly higher, 1:8300 and 1:14,800
respectively. Additionally, the carrier frequency in the general
population is shown to be approximately one in 120.
From a clinical perspective, cases with BD present
with broad spectrum of neurological, dermatological
and systematic manifestations, ranging from seizures,
hypotonia, feeding problems, delayed motor and cognitive
development, ophthalmologic issues, hearing difficulties,
hair loss, eczematous skin rash and recurrent infections.
BD is included in the Recommended Uniform Screening
Panel for Newborn screening (NBS) by the Department
of Health and Human Services, United States of America,
which traces back to 1985 when a swift colorimetric assay
for evaluating biotinidase activity on dried blood spots
was developed. Collection of blood onto an absorbent
paper card, often referred to as a ‘Guthrie card’, is the
commonest type of NBS sample as shown in figure 01.
A few drops of blood from a heel prick are collected
onto a filter paper and sent to the laboratory for analysis.
In countries, like Pakistan that lack NBS, high risk
screening of suspected cases of BD is usually built upon
clinical findings, hyperammonemia, metabolic ketolactic
acidosis and the presence of 3-hydroxyisovaleric acid,
lactic acid, 3-hydroxypropionic acid, 3-mehtylcrotonyl
glycine and methyl citrate in the urine organic acid

analysis by gas chromatography mass spectrometry.
For the confirmation of diagnosis quantification of
biotinidase enzyme activity in serum/plasma is usually
recommended using tandem mass spectroscopy. Based
on the results, a diagnosis of profound (less than 10
percent of the mean normal biotinidase activity) or partial
(10-30 percent of mean normal biotinidase activity) BD
is established. Molecular analysis based on identification
of biallelic pathogenic variants in biotinidase gene is
considered when the results of enzymatic testing are
equivocal in differentiating profound from partial BD
and further evaluation is necessary.
Cases with BD identified by NBS continue to be
symptom free and show normal development if biotin
therapy is introduced promptly and uninterruptedly.
The simple, relatively inexpensive and widely available
treatment is usually based on 5-10 mg of oral biotin per
day. Furthermore, cases with profound and partial BD,
even diagnosed at later stages due to lack of NBS have
shown good outcomes and better prognosis on treatment
with oral biotin. In context of cost effective screening
tests, availability of confirmatory assays, in expensive
and widely available treatment, the prognosis of BD is
better compared to other enzyme defects and organic
acidemias, provided timely initiation and compliance
with therapy. The monitoring is done clinically and
periodic follow-up visits with the metabolic physician
are needed to ensure that the features of the condition
have resolved with therapy.

Figure 1 showing Heel Prick on dried blood spot filter paper for
DBS-Biotinidase analysis
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Renal Tubular Disorders and Biochemical
Diagnostics
Dr Siraj Muneer and Ms Iffat Arman
Clinical Chemistry

Renal tubules play an important role in fluid, electrolyte
and acid-base homeostasis. Normal reabsorption of
electrolytes, glucose, calcium, magnesium, phosphates
and amino acids and secretion of protons occur in
various specialized parts of the renal tubule. Tubular
dysfunction should be observed in all children with
hypokalemia and metabolic acidosis, failure to thrive,
polyuria, refractory rickets. Common disorders of renal
tubular dysfunction are shown in Table 1.
Table 1: Common Disorders of Tubular Functions
Segment

Function

Proximal tubule

Amino acid transport
Bicarbonate transport
Phosphate transport
Glucose transport
Chloride, potassium, sodium transport
Sodium, chloride transport
Proton (H+) secretion

Ascending limb of Henle
Distal tubule
Collecting duct

Sodium, potassium transport
Water transport

Assessment of Renal Tubular Acidosis (RTA)
The clinical features suggestive of renal tubular
disorders are refractory rickets, unexplained
hypertension (Liddle’s syndrome), growth retardation,
failure to thrive, polyuria, polydipsia; preference for
savory foods, renal calculi, nephrocalcinosis etc.
On laboratory investigation these patients present
with hypercalciuria with normal serum calcium,
hyponatremia with hyperkalaemia, metabolic alkalosis
with or without hypokalemia and hyperchloremic
metabolic acidosis. The following laboratory findings
are helpful in evaluating and classification of RTA.
Plasma anion gap: Anion gap shows the difference of
unmeasured anions and cations in the plasma, and is
measured as follows: Anion gap = Na+ – (Cl– + HCO3–).
Normal plasma anion gap is 10-12 mEq/L. Normal
anion gap in the presence of acidosis (hyperchloremic
metabolic acidosis) suggests elevated urinary (proximal
24

RTA) or gastrointestinal loss (diarrhea) of bicarbonate
or impaired excretion of H+ ions (distal RTA).

Urine anion gap: Urine anion gap (net charge)
(urine Na+ + K+ – Cl–) gives an estimate of urinary
ammonium (NH4+) excretion and is beneficial
in the evaluation of hyperchloremic acidosis.
Under normal circumstances, urine anion gap is
positive due to the presence of dissolved anions
e.g., sulfates, phosphates. Metabolic acidosis is
link with a compensatory rise in NH4+ production,
resulting in a negative
Disorder
urine anion gap. Patients
Aminoaciduria
with RTA typically
Proximal RTA
Hypophosphatemic rickets
represents impaired renal
Renal glucosuria
NH4+ excretion and a
Bartter syndrome
positive urine anion gap.
Gitelman syndrome
Distal RTA
Urine pH: Urine pH is
Liddle syndrome
Pseudohypoaldosteronism
Nephrogenic DI

an estimate of the number
of free H+ ions in the urine
which are secreted in
response to metabolic acidosis. The presence of alkaline
urine during metabolic acidosis represents defective
renal acidification, as in distal RTA. However, alkaline
urine may also be found in patients with metabolic
acidosis due to extra-renal disorders, as in diarrhea.
Fractional excretion of bicarbonate: The proximal
tubule normally reabsorbs almost all filtered bicarbonate
(fractional excretion below five percent). A value more
than 10 percent indicates proximal RTA while levels
are in the normal range in distal RTA. Proximal tubular
handling of bicarbonate can be evaluated by fractional
excretion of bicarbonate.
urine bicarbonate x plasma creatinine
Fractional excretion =
x100
of bicarbonate		plasma bicarbonate x urine creatinine

Tests for Potassium Handling
Renal tubular disorders may be associated with both
hypokalemia and hyperkalemia.
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The fractional excretion of potassium (FEK) may
also be used as an indicator of tubular function;
FEK values <2 indicates extra-renal causes while >2
indicates renal causes.
		urinary potassium x plasma
osmolality
Transtubular gradient of potassium =
		
plasma potassium x urinary osmolality

We can differentiate patients into three types
of tubular disorders based on these routine
biochemical tests, shown in table 2. Identification
of correct type of disorders is critical to patient
management. Hence it is imperative that all
patients suspected of any renal tubular disorder are
investigated thoroughly and managed accordingly.

Table 2: Differential Diagnosis in various types of Renal Tubular Acidosis
Type I (Distal)
Primary Defect

Metabolic Acidosis
(Hyperchloremic)
Serum K
Urinary Anion Gap
Urine pH
Fractional HCO-3 Excretion
Fractional K Excretion
NH4+ Excretion
Calcium Excretion
Citrate Excretion
Nephrocalcinosis/Lithiasis
Bone Involvement
Other Tubular Defects
+

H+ Secretion in the distal tubules
With HCO-3
Classic
wasting (Type
Hyperkalemic
III)

Type II
(Proximal)

Type IV

HCO-3
reabsorption in
the Proximal CT

Disruption of the reninangiotensin-aldosterone
axis

Yes

Yes

Yes

Yes

Yes

Normal/Low
Positive
>5.5

Normal/Low
Positive
>5.5

High
Positive
>5.5

Normal/Low
Negative
<5.5

High
Positive
<5.5

<5 percent
High
Decreased
Increased
Decreased
Often Present
Rarely Present
Absent

>5-15 percent
High
Decreased
Increased
Decreased
Often Present
Rarely Present
Absent

<5 percent
Low
Decreased
Increased
Decreased
Often Present
Rarely Present
Absent

>10-15 percent
Normal/High
Normal
Normal
Normal
Absent
Often Present
Often Present

>5-10 percent
Low
Decreased
Normal/Decreased
Normal
Absent
Absent
Absent

Utility and application of Chromosomal
Microarray (CMA) in Clinical Diagnostic
Zeeshan Ansar, Asghar Nasir, Nazneen Islam
Molecular Pathology

Introduction
The chromosomal microarray, also termed cytogenetic
microarray, molecular karyotyping, or genomic copy
number array, is a deoxyribonucleic acid (DNA)-based
testing method used to identify copy-number variants
(CNVs), which are either gains (i.e. duplications)
or losses (i.e. deletions) of genomic material. This
assay is a high resolution, whole-genome screening
technique that can identify most of the chromosomal
imbalances detected by conventional cytogenetic
analysis, as well as smaller submicroscopic deletions

and duplications that are referred to as copy-number
variants (CNVs).Various human disorders may be
caused by CNVs, including neurodevelopmental
disorders and congenital anomalies such as cardiac
defects. CMA is recommended as the first-tier test in
the postnatal evaluation of congenital abnormalities
and neurodevelopmental disorders as well as other
constitutional or congenital diseases.
CMA in particular is recommended when genetic
analysis is performed in cases with clinical structural
anomalies and/or karyotypical anomalies identified.
25
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CMA should be considered as further evaluation
when an apparently balanced de novo rearrangement
is detected by karyotyping to exclude an imbalance at
one or both of the translocation breakpoints.
CMAs study is also proved to be helpful tool in
identifying the chromosomal origin and gene content
of marker or ring chromosomes identified with
conventional karyotype
Indications of CMA
Chromosomal microarrays are recommended
as a screening test by the American College of
Medical Genetics when there is a family history of
chromosomal abnormalities and there is a normal
karyotype but suspected genetic conditions.
Investigations could include; 1) identification of
congenital genetic defects, 2) characterization
of acquired genetic changes 3) determination of
genomic variations and polymorphisms 4) individuals
with multiple congenital anomalies, developmental
delay/intellectual disability, and/or autism spectrum
disorders, with clinically significant findings reported
in approximately 15 percent of cases with normal
conventional karyotypes
Therefore, CMA should be considered for clinical
presentation of:
•
•
•
•
•

Isolated autism spectrum disorder (ASD) or
ASD plus other findings
Isolated global developmental delay or
intellectual disability
Multiple congenital anomalies in the absence
of a syndrome diagnosis
Unusual physical features (dysmorphisms)
Recurrent miscarriages

Limitations of CMAs
Limitations of the use of CMAs include:
1. The inability to detect genetic events that
do not affect the relative copy number of DNA
sequences, for example., molecularly balanced
chromosomal rearrangements. However, CMAs
may reveal copy number changes in apparently
26
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“balanced” chromosomal rearrangements, i.e.,
gains or losses, at or near the chromosomal
breakpoint sites.
2. Low-level mosaicism for unbalanced
chromosomal rearrangements and aneuploidy
may not be detected by CMAs. The sensitivity of
the microarray for detection of mosaicism will
be influenced by the platform, sample type, copy
number state, DNA quality, data quality, and
size of imbalance.
3. The chromosomal mechanism of a genetic
imbalance may not be clarified.
4. Tetraploidy or other ploidy levels may not be
detected or may be difficult to detect.
5. Genomic regions copy number variations 		
(CNVs) is not represented on the platform.
6. Current CMA technologies are not designed
to detect duplications and deletions below
the level of detection according to probe
coverage and performance, point mutations, gene
expression, and methylation anomalies that may
contribute to the patient’s phenotype.
7. No microarray platform will detect all
mutations associated with a given syndrome.
Therefore, failure to detect a copy number
alteration at any locus does not exclude the
diagnosis of a disorder associated with that
locus.
Developmental delay (DD) and intellectual
disability (ID) are estimated to affect ~ 1 percent
of the children across the world. Genetic factors
play a major part in DD/ ID (up to ~ 47.5 percent).
Identification of the genetic cause is crucial for
accurate etiological diagnosis and refined clinical
management. Chromosomal microarray analysis
(CMA) has been recommended as a first-tier
genetic test for unexplained DD/ID and congenital
malformations. The reported diagnostic yields of
clinical CMA vary between 12 and 20 percent,
depending on the population and methods used.
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Algorithm for use of chromosomal microarray analysis (CMA)

Diagnostic Testing

Clinical and Family history

No Clinical and family history

Constitutional/Congenital disease
Significant Clinical finding on radiology/Other Labs

CMA+ Karyotypes

FISH/Karyotypes

Normal

Abnormal

CMA

TSH Receptor Antibodies (TRAb) in Neonatal
Hyperthyroidism: What We Need to Know?
Dr Zaib-un-Nisa
Clinical Chemistry

Neonatal hyperthyroidism, also known as neonatal
Graves’ disease (NGD), is a rare disease occurs due to the
Trans-placental passage of maternal stimulating TSH
receptor antibodies (TRAb). It is mostly transient and
permanent non-autoimmune neonatal hyperthyroidism
is rare and is due to activating mutations of TSH receptor.
Exposure to topical iodine has also been reported as
a rare cause of hyperthyroidism in newborns. If it is
not diagnosed early and treated correctly, can leads
permanent intellectual disability in the baby.

Graves’s hyperthyroidism occurs in approximately
0.2 percent of women, and approximately one to five
percent of infants born to these mothers developed
NGD. TRAb are Immunoglobulin of G class and
freely cross the placenta. Most NGD occurs in the
setting of active or treated Graves’s hyperthyroidism
in the mother. Thus, NGD would be expected to
occur in approximately 1: 25,000 neonates and
affects males and females equally.
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Any
infant
with
unexplained Table 1: Clinical Spectrum of the NGD presenting in prenatal period and neonates.
tachycardia, goiter or stare, unexplained Age Group
Clinical Features
petechiae,
hyperbilirubinemia,
or
Prenatal Period (Fetus)
• Unexplained tachycardia,
hepatosplenomegaly,
history
of
• Failure to thrive
persistently high TRAb titer in mother
• Intrauterine growth retardation
during pregnancy, persistently high
• Goiter
• Advanced bone age
requirement for any thyroid medication
• Prematurity
in mother during pregnancy, thyroid
• Craniosynostosis, microcephaly
ablation for hyperthyroidism in mother
• Fetal death
or previously affected sibling should
Neonate
• Irritability, hyper excitability, sleep disorders
be further investigated for NGD. The
• Tachycardia, hypertension, cardiac failure
clinical manifestation of NGS are shown
• Flushing, sweating, Goiter, stare
• Respiratory distress, pulmonary hypertension
in Table 1.
• Increased appetite but no/poor weight gain
• Diarrhea
For evaluation of any neonate suspected
• Unexplained petechiae, hyperbilirubinemia
with the NGD, serum TRAb, TSH and
• Craniosynostosis, microcephaly,
FT4 testing is recommended. A low TSH,
• Death
high FT4 along with TRAb levels higher
unlikely to become hyperthyroid. At Aga Khan Clinical
than three-fold the upper limit of normal
Laboratories we are performing serum TRAb levels,
within 7 days of birth is predictive of the NGD. And
using Chemiluminescence immunoassay..
if the TRAb levels are not detectable, the baby is very

Webinar ‘Newborn Screening Program: An
Impetus for change’ in a webinar series ‘Rare
Links’
Dr Hafsa Majid
Clinical Chemistry

An online educational webinar series ‘Rare Links’
was initiated by Section of Chemical Pathology
since December 2019, from the platform of Pakistan
Inherited Metabolic Disease Network (Pak-IMD-Net),
a working group of Pakistan society of Chemical
Pathology. Aim of Rare links webinar series is to
provide a platform where national and international
experts can share their knowledge and experience
of developed and developing newborn screening
programs in and approaches to developing this in
Pakistan. The webinar will feature presentations on the
elements of a newborn screening program; talks on
experiences and challenges of implementing newborn
screening programs. Third webinar of this series was
conducted via Zoom video conferencing on ‘Newborn
28

Screening Program: An Impetus for change’ on 22nd
September 2020.
The focus of workshop was on understanding the
basic concepts, components of a complete newborn
screening program, and relate criteria for disorder
selection to their individual circumstances. Webinar
started with introduction of all participants followed
by a talk by chair Pak-IMD-Net, Dr Lena Jafri. She
briefed the participants about the aims and objectives
of this working group and how Pak-IMD-Net is raising
awareness about NBS. This was followed by lecture
about ‘Laboratory Aspects of Newborn screening:
What you need to know for establishing a NBS
laboratory’ by Prof. Dr. Aamir Ijaz, co-chair, Pak-IMD-
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Net. This was followed by introduction to “rare links’
webinar series by Dr. Hafsa Majid. She shared the
experience of establishing a successful NBS program
at the Aga Khan University. Next was a talk given by
Dr Aysha Habib Khan, Advisory council member for
Society for Studies on inherited metabolic disorders, to
further our understanding of the selecting the disorder
to be include in NBS program established for Pakistani
setup. She presented findings of the consensus report
from the conference on ‘NBS in Pakistan’ conducted
in 2019.
The program concluded with panel discussion by
national and international expert on ‘Developing
Policy Recommendations for starting Nationwide
NBS program in Pakistan’. The panelist included Dr
Dianne Rosemary Webster, Director NBS program of
New Zealand, Prof. Dr. Layachi Chabraoui, President
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Moroccan Society for Study of Inborn Errors of
Metabolism, Dr. Khadija Humayun, Associate
Professor and Consultant Paediatric Endocrinologist,
Paediatric and Child Health, Aga Khan University,
along with the presenters.
It was a remarkably successful event, with more
than 70 participants from 3 different countries,
17 different cities, and 34 different institutes of
Pakistan. The participants were from different areas
of medicine including Paediatrics, Laboratory
Medicine, Gynecology and Obstetrics, nursing,
Family Medicine, Internal Medicine, and Public
Health sectors. This was the third webinar of this
series, and it was very well appreciated by all the
participants. The participants encouraged organizers
to conduct more such activities under the banner of
‘Rare Links’.

The Best of the Past
Radiologist # Paediatricimaging # Followtheirlead
Interviewee: Associate Prof Naila Nadeem
Interview recorded by Dr. Shayan Anwar
1. Considering your entire time as paediatric
imaging radiologist at your organization, can you
recall a time (any AHAA moment) when you felt
most alive or most excited about your involvement
in the organization?
Prof Naila Nadeem: Every moment of my clinical
experience in AKU has been worth narrating, however
the most AHAA moments were when I worked
with the multi-disciplinary team in management of
“Conjoint Twins”, starting from imaging, then surgery
and management was challenging. It is one of the best
example of team work. I just could not stop my tears
when I met the twins, separately held by parents, both
healthy and happy.

2. Please briefly share your initial phase of
journey i.e. from medical graduate to consultant.
Prof Naila Nadeem: Long journey, I have worked
in four different government hospitals immediately

after graduation, did
my minor Diploma
(MCPS) in radiology.
The quest for better
training made me
apply in the residency
program of AKU. I was
fortunate to get selected
as a resident in AKU in
1997. I have no regrets
to leave my consultant
position in government
job for a better training. My young and energetic
batch mates kept me on my toes. Colleagues were
supportive, respectful but challenged me every day.
University is very supportive, I was encouraged
to excel not only as a clinician but also as an
educationist, I did MHPE which has further tested
my endurance but is rewarding. I enjoy Paediatric
radiology and medical education.
29
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3. Let’s consider for a moment the things you
value deeply. Specifically, the things you value
about yourself and the nature of your work, what
is the single most important thing your work has
contributed to your life?
Prof Naila Nadeem: Discipline, excellent work-place,
lifelong learning desire all have contributed, but what
has really affected me most is “altruism”. This is
the splendor of AKU, it induces into us the “selfless
concern for the well-being of our patients and for our
colleagues”.
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to him for leading and building the team with open
mind. Now Paediatric imaging is an established
separate field in Pakistan. It is established in Karachi,
Lahore, Multan and Islamabad. We now have our
representation in radiology Society of Pakistan. At
College of Physician Surgeons Pakistan (CPSP) level
we are trying to establish fellowship programme.
In next ten years I see further progress of paediatric
radiology, as more and more dedicated centers for
paediatric care are established. Still long way to go but
we are very hopeful.
5. Any advice for Junior Radiologists?

4. As a senior Paediatric imaging radiologist
of the country, please share your experience of
development of paediatric imaging practices in
Pakistan and its future in next 10 years.
Prof Naila Nadeem: When I joined Paediatric imaging
group, Dr. Yousuf was the only name, I am grateful

Prof Naila Nadeem: Be happy and gratified
physicians, live up to your title “The Doctor”. Work
with dedication for your patients. Role models like
Dr. Gaffar Billoo teach us there is no age limit for
learning and work hard. The smile on your patients’
face is the biggest reward, try to earn that.

The Best of the Past
Interview of the Professor of Pathology and Laboratory Medicine,
Interviewee: Professor Aysha Habib Khan
Interview Recorded by Dr Syed Bilal Hashmi
1. Please share a brief journey/experience of
establishing a Biochemical Genetics Laboratory?
Professor Aysha Habib Khan: I take pride in the 10
years I have invested in realization of BGL and have
a great sense of gratitude when I look back. In 1995
after moving from paediatric residency to chemical
pathology, I felt a major gap in the diagnostics of inborn
errors of metabolism, this then became my passion to
contribute towards this area of metabolic medicine.
There was a genuine need of Biochemical Genetic
Laboratory (BGL) for the community and healthcare.
Establishing BGL was not an easy task and consumed
10 extensive years after my post-graduation.
Starting from advocacy down to planning and
implementation and now, representing AKU and
Pakistan in international forums are accomplishments
30

that are difficult to
describe and express.
All I know is a strong
foundation has been
laid and now the entire
BGL team including
my technologists and
faculty have got to give
their best to reap fruits.
Complete
diagnostic
setup will take its time
but continuing in the
right direction and developing & training younger lot
to take it forward with updated knowledge and latest
technique is the need for future.
2. What challenges did you face in establishing
and leading the Biochemical genetics laboratory?
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Furthermore, what were the success factors that
helped you respond to these challenges?

4. What contribution is the Biochemical genetics
laboratory paying towards patient benefit?

Professor Aysha Habib Khan: As I said earlier,
advocacy was the major challenge, which consumed
significant time. Establishing a new specialty requires
substantial resources, and with limited funds for entire
hospital, it was not easy convincing decision makers
to invest on something very new. New in a sense that
biochemical genetic diagnostics specialty did not
existed in Pakistan, with no data to prove that inherited
metabolic disorders exist in sufficient numbers to be
of public importance. The good part was that related
clinical fraternity was cognizant of the missing facility
and therefore, supported this endeavor voice fully.

Professor Aysha Habib Khan: Now that the lab is
formally accredited by college of American Pathologist;
the most important and valuable contribution is access
and prompt diagnosis from within AKU, thus saving a
lot of time and providing financial relief to the family.
The second important factor is close interaction and
trust between treating physician and pathologist.

My perseverance and focused approach to achieve
genetic lab objective was the main factor in overcoming
the challenge. Despite of non-availability of funds,
always enhancing my knowledge and remaining abreast
of the happening and advancements taking place in the
field further strengthening my zeal to equip the lab with
genetic diagnostic facilities.
3. Can you share any success story or “AHA
Moment” where you felt very excited while making
a diagnosis?
Professor Aysha Habib Khan: The AHA moment to
me was also the first milestone for us, in diagnosing
the first case with inherited metabolic disease in
“real time’. It so happened that before our services
were operationalized; we were approached by Dr
Bushra Afroze for a patient admitted in NICU for
a clinical suspicion of a metabolic disorder and
requested our support to determine the diagnosis. It
was a weekend and on analysis it was identified to be
a case of isovaleryl CO A dehydrogenase deficiency.
Why I called it a milestone was with the reason
that the lab team had before operationalizing got
its first result tested, verified and communicated to
the treating physician. Actual benefit was saving a
precious neonate’s life, which otherwise would not
have happened, unless the specimen was sent abroad
for testing for verification. A heartening thank you
note from Dr Bushra Afroze was not only a source
of excitement for the team, but also a sense of
accomplishment and a valuable contribution in the
treatment of children, who were otherwise delayed
for multiple reasons.

5. What are the plans or vision for the next ten
years?
Professor Aysha Habib Khan: We started small
with just two equipments, but with a test menu that
had maximum diagnostic yield. Now we are moving
forward on optimizing and validating assays on HPLC
and LCMSMS. With this, we will be able to expand our
test menu and capture disorders that were not picked
earlier. This would also provide opportunity to study
the spectrum of diseases within Pakistan.
We have also laid down infrastructure and standard
operating procedures for newborn screening program
at AKUH. We started with screening for congenital
hypothyroidism and now moving to screening for
congenital adrenal hyperplasia. We hope to expand it
for expanded newborn screening once the assays are
validated.
We have focused on human resource capacity building
to oversee the specialty. These include eight faculty
members including myself and 12 technologists.
Intention is to train more faculty and technologist
to ensure that gap does not not arise at any stage.
Our faculty is now leading from front and we are
collaborating with various international organizations
including Mayo Laboratory in US and Society of Study
of Inborn Errors of Metabolism (SSIEM).
At the same time, we have worked on developing
the national capacity of physicians, pathologists and
technologists across Pakistan through numerous
conferences, continuing medical education, seminars,
hands on workshops and other training ventures.
Our intentions is to contribute nationally, developing
human resource capacity to carryout diagnostics
and interpretation of biochemical genetics data and
facilitate families in all cities, regions and provinces
31
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of Pakistan. This is how we would be able to serve
community at large in line with Chancellor’s vision.
We hope to develop patient’s registries and support
groups for raising awareness and education on genetic
diseases for masses in future.
6. What advice will you give to the junior pathologist
persuading career in the field of Biochemical
genetics?
Professor Aysha Habib Khan: I would encourage

participation from the seniors to nurture the juniors
and for the juniors and newcomers to take on
this field with zeal and enthusiasm. Biochemical
genetics will now grow at a faster pace in Pakistan
and youngsters wishing to pursue a career in this
specialty will have a very bright future. To get into
this field, one must have analytical approach and
research aptitude. A strong foundation has been laid
by AKUH. Developing & training younger lot to
take it forward with updated knowledge and latest
technique is the need for future.

Polaroid

Histopathologists after conducting Paediatric Tumor Boards of multiple subspecialties
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Polaroid

Reporting of Flow Cytometry cases of Paediatric Hematological Malignancies

Laboratory technical staff processing Paediatric Blood Culture bottle that was flagged positive in continuous blood culture
monitoring system
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Polaroid

Positive Latex Particle Agglutination (LPA) test for Neisseria Meningitidis in Paediatric patient with suspected community
acquired Meningitis

A Lab Scientist performing Sweat Chloride testing to Screen for Cystic Fibrosis in a patient
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Polaroid

Faculty and Technologists of Chemical Pathology discussing the Chromatograms of Plasma Amino Acids and Urine
Organic Acids in Departmental Consultation Conference

Paediatric Imaging Team Aga Khan University Hospital at Radiological Society of Pakistan: (left to right) - Dr Kiran Hilal,
Dr Naila Nadeem, Dr Yousuf Husen, Dr Waseem Mirza and Dr Basit Salam
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Polaroid

Faculty, Laboratory technologist (Genetics bench) and Laboratory Manager at the section of Molecular Pathology,
Clinical Laboratory, AKUH that are involved in paediatric molecular diagnostics

Computer analysis is used to compare a patient’s genetic material to that of a reference sample.
A difference between a patient’s DNA and the reference sample is called a genetic variant.
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Polaroid

Haematology resident and blood bank staff performing and interpreting neonatal blood group by gel card method

Chief Guests at the Launch of Ek-Sath- an eportal for the support of patients and families with rare inherited metabolic
defects (IMDs) in Pakistan
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hospitals.aku.edu/Karachi/clinical-laboratories
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